Shots:
Merck Animal Health has entered into a definitive agreement to acquire TARGAN for an undisclosed purchase price; closing is expected in Q3’26
Upon closing, the acquisition will expand MAH’s poultry portfolio with WingScan, an automated chick sorting platform that uses vision tech & proprietary algorithms to identify & sort chicks by gender in real…
Shots:
Novanta has entered into a definitive agreement to acquire Riverpoint Medical from Arlington Capital Partners, expanding Novanta’s presence in the minimally invasive surgery market
As per the deal, Novanta will acquire Riverpoint for $1.2B upfront, with $250M in milestone payments expected in Q1’27, representing the total deal value of $1.45B; closing is anticipated in…
Shots:
GSK has entered an agreement to acquire Nuvalent, accelerating its entry into lung cancer
As per the deal, GSK will acquire Nuvalent through a tender offer of $124 per share in cash, valuing the company at ~$10.6B (£8.0B); net of acquired cash, GSK’s total investment is estimated at $9.4B (£7.1B). Closing is expected in…
Shots:
J&J has entered into a definitive agreement to acquire Firefly Bio, incl. its Firelink degrader antibody conjugate (DAC) platform, expanding its oncology pipeline
As per the deal, J&J will acquire Firefly Bio for $1B in cash, with closing expected later this year
The Firelink DAC platform is a targeted protein degradation tech that selectively…
Shots:
Incyte has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, to expand its hematology portfolio into bleeding disorders
As per the deal, Incyte will acquire Vega for $1.25B upfront, with ~$750M in additional payments upon achievement of sales milestones
Acquisition will expand Incyte’s hematology portfolio with…
Shots:
Rallybio has entered into a definitive agreement to acquire Avenzo through a merger transaction, after which the combined company will operate under the name Avenzo Therapeutics & is expected to trade on Nasdaq under the ticker symbol "AVZO"
As per the deal, Avenzo shareholders will receive newly issued Rallybio shares based on the companies’…
Shots:
Servier has entered into an agreement with Edgewise Therapeutics to acquire its muscular dystrophy business, supporting Servier’s strategic ambition in rare neurology
As per the deal, Servier will acquire the muscular dystrophy business for ~$2.65B, incl. $1.55B upfront and ~$1.1B in regulatory & commercial milestone payments; closing is expected in Q3’26
The acquisition adds Edgewise’s…
Shots:
Eli Lilly will acquire 3 companies, Curevo, LimmaTech Biologics, & Vaccine Company, to build its infectious disease portfolio through differentiated vaccine & platform technologies
The deals incl. Curevo’s P-II shingles vaccine candidate amezosvatein, LimmaTech’s P-I vaccine LTB-SA7 targeting S. aureus infections, & Vaccine Company’s preclinical EBV vaccine platform leveraging proprietary in vivo nanoparticle technology
As…
Shots:
Olympus has entered into a definitive agreement to acquire BioProtect, incl. its Balloon Spacer system designed to protect healthy tissue during prostate cancer radiotherapy
As per the agreement, Olympus will acquire BioProtect in a deal valued at ~$270M, with certain amounts held in escrow subject to uninterrupted business operations; closing is expected by the…
Shots:
A consortium led by CVC and GBL launched a voluntary cash tender offer to acquire Recordati at €51.29/share, valuing the transaction at ~€10.7B (~$12.4B). The offer aims to delist Recordati from Euronext Milan & is expected to close in Q4’26
The offer is backed by Rossini, which agreed to tender its 97.9M shares (~46.8%…

